Asxl1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Authors

Amro Elshoury
Han Yu
Peter A. Kouides, Rochester Regional HealthFollow

Department

Oncology and Hematology

Document Type

Conference Proceeding

Publication Title

Blood

Conference Name

ASH Annual Meeting

Conference Date

2021-11-05

Abstract

Background: Bleeding and thrombosis are prevalent across all myeloproliferative neoplasm (MPN) subtypes and have significant impact on morbidity and mortality. Although risk factors for thrombosis are well established, bleeding risk factors in these patients are poorly characterized. Identifying MPN patients at higher risk for bleeding could guide the duration of anticoagulation for patients with MPN associated thrombosis (balancing the risk between bleeding and thrombosis), select individuals at higher risk for bleeding during prophylactic anticoagulation, and predict for bleeding complications with surgical procedures.

First Page

3637

DOI

10.1182/blood-2021-146384

Volume

138

Issue

Supplement 1

Publication Date

11-23-2021

Comments

See full list of authors at journal website.

634.MYELOPROLIFERATIVE SYNDROMES: CLINICAL AND EPIDEMIOLOGICAL

Recommended Citation

Elshoury, A., Yu, H., & Kouides, P. A. (2021). Asxl1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN). Blood, 138 (Supplement 1), 3637. https://doi.org/10.1182/blood-2021-146384